Shelley McCloskey
Human Resources Officer at XENON PHARMACEUTICALS INC.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ian Mortimer | M | 48 | 11 years | |
Simon Pimstone | M | 56 | 28 years | |
Clarence Machado | M | 60 | 4 years | |
Mohammad Azab | M | 68 | 21 years | |
Sherry Aulin | F | 40 | 13 years | |
Elizabeth Garofalo | M | 66 | 3 years | |
Andrea DiFabio | F | 55 | 2 years | |
Dawn Svoronos | F | 70 | 8 years | |
Jodi Regts | F | - | 9 years | |
Steven Gannon | M | 62 | 9 years | |
Gary Patou | M | 65 | 20 years | |
Robin Sherrington | M | 63 | 23 years | |
Sheila M. Grant | F | - | 4 years | |
James Empfield | M | - | 8 years | |
Chris von Seggern | M | - | 4 years | |
Gillian Cannon | M | 60 | 1 years | |
Justin Gover | M | 53 | 1 years | |
Christopher Kenney | M | - | 3 years | |
Michael Rogawski | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Frank Holler | M | 67 | 25 years | |
Michael Hayden | M | 72 | 26 years | |
Barbara Troupin | M | 56 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 2 years |
Michael Tarnow | M | 79 | 22 years | |
Richard Scheller | M | 70 | 5 years | |
Richard Levy | M | 66 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 2 years |
Clarissa Desjardins | M | 57 | - | |
Kelvin Neu | M | 50 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 2 years |
David Mitchell | M | 67 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 3 years |
Fares Boulos | M | - |
Xantrex Technology, Inc.
Xantrex Technology, Inc. SemiconductorsElectronic Technology Xantrex Technology, Inc. manufactures power supplies. It specializes in charger and inverter, power inverter, battery charger and backup power. The company is headquartered in Burnaby, Canada. | - |
Ernesto Aycardi | M | 61 | 3 years | |
Abbey Jenkins | F | - |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | - |
Alexandra Mancini | F | - | 4 years | |
Brad Forth Forth | M | 59 |
Xantrex Technology, Inc.
Xantrex Technology, Inc. SemiconductorsElectronic Technology Xantrex Technology, Inc. manufactures power supplies. It specializes in charger and inverter, power inverter, battery charger and backup power. The company is headquartered in Burnaby, Canada. | 3 years |
Paul Brennan | M | - |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 2 years |
Stephen Shrewsbury | M | 67 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 3 years |
Jean-François Heitz | M | 73 |
Xantrex Technology, Inc.
Xantrex Technology, Inc. SemiconductorsElectronic Technology Xantrex Technology, Inc. manufactures power supplies. It specializes in charger and inverter, power inverter, battery charger and backup power. The company is headquartered in Burnaby, Canada. | - |
Lionel G. Dodd | M | 84 |
Xantrex Technology, Inc.
Xantrex Technology, Inc. SemiconductorsElectronic Technology Xantrex Technology, Inc. manufactures power supplies. It specializes in charger and inverter, power inverter, battery charger and backup power. The company is headquartered in Burnaby, Canada. | 3 years |
Larry D. Sanders | M | 78 |
Xantrex Technology, Inc.
Xantrex Technology, Inc. SemiconductorsElectronic Technology Xantrex Technology, Inc. manufactures power supplies. It specializes in charger and inverter, power inverter, battery charger and backup power. The company is headquartered in Burnaby, Canada. | 4 years |
Mary Yaroshevsky-Glanville | F | 59 |
1322256 Alberta Ltd.
1322256 Alberta Ltd. Pharmaceuticals: MajorHealth Technology Inex Pharmaceuticals Corporation is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. | 6 years |
Jason Robertson | M | - |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 39 | 97.50% |
United States | 1 | 2.50% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Shelley McCloskey
- Personal Network